发明名称 TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME
摘要 The invention provides tricyclic sulfonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.;
申请公布号 US2014378462(A1) 申请公布日期 2014.12.25
申请号 US201314372893 申请日期 2013.01.17
申请人 Zafgen, Inc. 发明人 Pallin Thomas D.;Dyke Hazel J.;Cramp Susan M.;Zahler Robert
分类号 C07D491/052 主分类号 C07D491/052
代理机构 代理人
主权项 1. A tricyclic compound represented by: wherein: T, Y and Z are independently selected from the group consisting of: CH or N, and wherein one or two of T, Y and Z is nitrogen; D is a 5-6 membered heterocyclic, carbocyclic or heteroaromatic ring; X is selected from the group consisting of: +—W1—*, +—W2—C(RD3RD4)—*, +—W2—C(O)—*, +—C(RD1RD2)—W3—*, in which the attachment points are indicated by + and * in X and in Formula I; W1 is selected from the group consisting of: O, N(RN1) or S; W2 is selected from the group consisting of: O or N(RN2); W3 is selected from the group consisting of: O or N(RN3); A is a ring selected from the group consisting of: phenyl, a 5-6 membered heteroaryl having 1, 2 or 3 heteroatoms each selected from S, N or O, and a 4-7 membered heterocycle having 1, 2 or 3 heteroatoms each selected from N or O; RA1 is selected, independently for each occurrence, from the group consisting of: hydrogen, hydroxyl, cyano, halogen, C1-4alkyl or C1-3alkoxy; wherein C1-4alkyl, or C1-3alkoxy may be optionally substituted by one or more fluorines; n is 1 or 2; RA2 is selected from the group consisting of: hydrogen, RiRjN—, heterocyclyl, heterocyclyloxy, heterocyclyl-(NRa)—; wherein said heterocyclyl may optionally be substituted by one or more substituents selected from Rg and wherein if said heterocyclyl contains a —NH moiety that nitrogen may optionally be substituted by one or more groups Rh; or RA2 is selected from the group consisting of: C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkoxy, C3-6alkenyloxy, C3-6alkynyloxy, C3-6cycloalkoxy, (wherein w is 0, 1 or 2), C1-6alkyl-N(Ra)—, C1-6alkyl-N(Ra)-carbonyl-, C1-6alkylcarbonyl-N(Ra)—, C1-6alkyl-N(Ra)-carbonyl-N(Ra)—, C1-6alkyl-N(Ra)—SO2—, C1-6alkyl-S2—N(Ra)—, C1-6alkoxycarbonyl-N(Ra)—, C1-6alkylcarbonyl-N(Ra)—C1-6alkyl-, C1-6alkyl-N(Ra)-carbonyl-C1-6alkyl-, C1-6alkoxyC1-6alkyl-; wherein C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkoxy, C3-6alkenyloxy, C3-6alkynyloxy, C3-6cycloalkoxy, C1-6alkyl-N(Ra)-carbonyl-, C1-6alkylcarbonyl-N(Ra)—, C1-6alkyl-N(Ra)-carbonyl-N(Ra)—, C1-6alkyl-N(Ra)—SO2—, C1-6alkyl-SO2—N(Ra)—, C1-6alkoxycarbonyl-N(Ra)—, C1-6alkylcarbonyl-N(Ra)C1-6alkyl-, C1-6alkyl-N(Ra)-carbonyl-C1-6alkyl-, C1-6alkoxy-C1-6alkyl may optionally be substituted by RP, phenyl, phenoxy, heteroaryl, heteroaryloxy, heteroaryl-(NRa)—, heterocyclyl, heterocyclyloxy or heterocyclyl-N(Ra)—; and wherein said heteroaryl or phenyl may optionally be substituted with one or more substituents selected from Rf; and wherein said heterocyclyl may optionally be substituted by one or more substituents selected from Rg; and wherein if said heterocyclyl contains a —NH moiety that nitrogen may optionally be substituted by one or more groups Rh; RD1 and RD2 are each independently selected from the group consisting of: hydrogen, fluorine, hydroxyl, C1-2alkyl or C1-2alkoxy; wherein the C1-2alkyl and C1-2alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano or hydroxyl; RD3 and RD4 are each independently selected from the group consisting of: hydrogen, fluorine, hydroxyl, cyano, C1-2alkyl or C1-2alkoxy; wherein the C1-2alkyl and C1-2alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or N(RaRb); RN1 is selected from the group consisting of: hydrogen or C1-2alkyl; RN2 is selected from the group consisting of: hydrogen or C1-2alkyl; RN3 is selected from the group consisting of: hydrogen, C1-3alkyl or C1-2alkylcarbonyl; wherein the C1-3alkyl and C1-2alkylcarbonyl may optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or N(RaRb); Ra and Rb are independently selected, for each occurrence, from the group consisting of: hydrogen and C1-3alkyl; wherein C1-3alkyl may optionally be substituted by one or more substituents selected from: fluorine, cyano, oxo and hydroxyl; or Ra and Rb, together with the nitrogen to which they are attached, may form a 4-6 membered heterocyclic ring which may have an additional heteroatom selected from O, S, or N; and wherein the 4-6 membered heterocyclic ring may optionally be substituted by one or more substituents selected from the group consisting of: fluorine, cyano, oxo or hydroxyl; Rf is independently selected, for each occurrence, from the group consisting of: RP, hydrogen, C1-6alkyl, C3-6cycloalkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkoxy, C1-6alkyl-S(O)w— (wherein w is 0, 1 or 2), C1-6alkylcarbonyl-N(Ra)—; C1-6alkoxycarbonyl-N(Ra)—; and wherein C1-6alkyl, C3-6cycloalkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkoxy, C1-6alkyl-S(O)w—, C1-6alkylcarbonyl-N(Ra)—, C1-6alkoxycarbonyl-N(Ra)— may be optionally substituted by one or more substituents selected from RP; Rg is independently selected for each occurrence from the group consisting of: RP, hydrogen, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkoxy, (wherein w is 0, 1 or 2), C1-6alkylcarbonyl-N(Ra)—, C1-6alkoxycarbonyl-N(Ra)—; wherein C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkoxy, C1-6alkylcarbonyl-N(Ra)—, C1-6alkoxycarbonyl-N(Ra)— may be optionally substituted by one or more substituents selected from RP; Rh is independently selected for each occurrence from the group consisting of: hydrogen, C1-6alkyl, C3-6alkenyl, C3-6alkynyl, C3-6cycloalkyl, C1-6alkyl-S(O)2—, C1-6alkoxycarbonyl-, RiRjN-carbonyl-, RiRjN—SO2—; wherein C1-6alkyl, C3-6alkenyl, C3-6alkynyl, C3-6cycloalkyl, C1-6alkyl-S(O)2—, C1-6alkylcarbonyl- may optionally be substituted by one or more substituents selected from RP; Ri and Rj, are selected independently for each occurrence from the group consisting of: hydrogen, C1-4alkyl and C3-6cycloalkyl; wherein C1-4alkyl and C3-6cycloalkyl may be optionally substituted by one or more substituents selected from fluorine, hydroxyl, cyano, RaRbN—, RaRbN-carbonyl-, C1-3alkoxy; or Ri and Rj taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring which may have an additional heteroatom selected from O, S, or N, optionally substituted on carbon by one or more substituents selected from the group consisting of: fluorine, hydroxyl, oxo, cyano, C1-6alkyl, C1-6alkoxy, RaRbN—, RaRbN—SO2—, RaRbN-carbonyl-; and wherein said C1-6alkyl or C1-6alkoxy may optionally be substituted by fluorine, hydroxyl or cyano; and optionally substituted on nitrogen by one or more substituents selected from the group consisting of: C1-6alkyl, RaRbN-carbonyl-; and wherein said C1-6alkyl may be optionally substituted by fluorine, hydroxyl, cyano; RP is independently selected, for each occurrence, from the group consisting of: halogen, hydroxyl, cyano, C1-6alkoxy, RiRjN-carbonyl-, RiRjN—SO2—, R1RjN-carbonyl-N(Ra)—; and pharmaceutically acceptable salts, stereoisomers, esters and prodrugs thereof.
地址 Cambridge MA US